Patricia Angela Sibal, Shigeru Matsumura, Toru Ichinose, Itzel Bustos-Villalobos, Daishi Morimoto, Ibrahim R Eissa, Mohamed Abdelmoneim, Mona Alhussein Mostafa Aboalela, Nobuaki Mukoyama, Maki Tanaka, Yoshinori Naoe, Hideki Kasuya
Oncolytic viruses (OVs) can selectively replicate in tumor cells and remodel the microenvironment of immunologically cold tumors, making them a promising strategy to evoke antitumor immunity. Similarly, agonists of the stimulator of interferon genes (STING)-interferon (IFN) pathway, the main cellular antiviral system, provide antitumor benefits by inducing the activation of dendritic cells (DC). Considering how the activation of the STING-IFN pathway could potentially inhibit OV replication, the use of STING agonists alongside OV therapy remains largely unexplored...
February 23, 2024: Molecular Oncology